TY - JOUR
T1 - International Nosocomial Infection Control Consortium (INICC) report, data summary of 45 countries for 2013-2018, Adult and Pediatric Units, Device-associated Module
AU - Rosenthal, Victor Daniel
AU - Duszynska, Wieslawa
AU - Ider, Bat Erdene
AU - Gurskis, Vaidotas
AU - Al-Ruzzieh, Majeda A.
AU - Myatra, Sheila Nainan
AU - Gupta, Debkishore
AU - Belkebir, Souad
AU - Upadhyay, Namita
AU - Zand, Farid
AU - Todi, Subhash Kumar
AU - Kharbanda, Mohit
AU - Nair, Pravin K.
AU - Mishra, Sanghamitra
AU - Chaparro, Gustavo
AU - Mehta, Yatin
AU - Zala, Dolatsinh
AU - Janc, Jaroslaw
AU - Aguirre-Avalos, Guadalupe
AU - Aguilar-De-Morós, Daisy
AU - Hernandez-Chena, Blanca Estela
AU - Gün, Emrah
AU - Oztoprak-Cuvalci, Nefise
AU - Yildizdas, Dincer
AU - Abdelhalim, Mona Moheyeldin
AU - Ozturk-Deniz, Suna Secil
AU - Gan, Chin Seng
AU - Hung, Nguyen Viet
AU - Joudi, Hala
AU - Omar, Abeer Aly
AU - Gikas, Achilleas
AU - El-Kholy, Amani Ali
AU - Barkat, Amina
AU - Koirala, Anjeela
AU - Cerero-Gudiño, Antonio
AU - Bouziri, Asma
AU - Gomez-Nieto, Katherine
AU - Fisher, Dale
AU - Medeiros, Eduardo A.
AU - Salgado-Yepez, Estuardo
AU - Horhat, Florin
AU - Agha, Hala Mounir Moustafa
AU - Vimercati, Julio César
AU - Villanueva, Victoria
AU - Jayatilleke, Kushlani
AU - Nguyet, Le Thi Thu
AU - Raka, Lul
AU - Miranda-Novales, María Guadalupe
AU - Petrov, Michael Mihailov
AU - Apisarnthanarak, Anucha
AU - Tayyab, Nadia
AU - Elahi, Naheed
AU - Mejia, Nepomuceno
AU - Morfin-Otero, Rayo
AU - Al-Khawaja, Safa
AU - Anguseva, Tanja
AU - Gupta, Umesh
AU - Belskii, Vladislav A.
AU - Mat, Wan Rahiza Wan
AU - Chapeta-Parada, Edwin Giovanny
AU - Guanche-Garcell, Humberto
AU - Barahona-Guzmán, Nayide
AU - Mathew, Anju
AU - Raja, Kavita
AU - Pattnaik, Saroj Kumar
AU - Pandya, Nirav
AU - Poojary, Aruna Ananda
AU - Chawla, Rajesh
AU - Mahfouz, Tahsine
AU - Kanj, Souha S.
AU - Mioljevic, Vesna
AU - Hlinkova, Sona
AU - Mrazova, Mariana
AU - Al-Abdely, Hail M.
AU - Guclu, Ertugrul
AU - Ozgultekin, Asu
AU - Baytas, Volkan
AU - Tekin, Recep
AU - Yalçın, Ata Nevzat
AU - Erben, Nurettin
AU - Mohamed Abbas, Amira
N1 - Publisher Copyright:
© 2021
PY - 2021/10
Y1 - 2021/10
N2 - Background: We report the results of INICC surveillance study from 2013 to 2018, in 664 intensive care units (ICUs) in 133 cities, of 45 countries, from Latin-America, Europe, Africa, Eastern-Mediterranean, Southeast-Asia, and Western-Pacific. Methods: Prospective data from patients hospitalized in ICUs were collected through INICC Surveillance Online System. CDC-NHSN definitions for device-associated healthcare-associated infection (DA-HAI) were applied. Results: We collected data from 428,847 patients, for an aggregate of 2,815,402 bed-days, 1,468,216 central line (CL)-days, 1,053,330 mechanical ventilator (MV)-days, 1,740,776 urinary catheter (UC)-days. We found 7,785 CL-associated bloodstream infections (CLAB), 12,085 ventilator-associated events (VAE), and 5,509 UC-associated urinary tract infections (CAUTI). Pooled DA-HAI rates were 5.91% and 9.01 DA-HAIs/1,000 bed-days. Pooled CLAB rate was 5.30/1,000 CL-days; VAE rate was 11.47/1,000 MV-days, and CAUTI rate was 3.16/1,000 UC-days. P aeruginosa was non-susceptible (NS) to imipenem in 52.72% of cases; to colistin in 10.38%; to ceftazidime in 50%; to ciprofloxacin in 40.28%; and to amikacin in 34.05%. Klebsiella spp was NS to imipenem in 49.16%; to ceftazidime in 78.01%; to ciprofloxacin in 66.26%; and to amikacin in 42.45%. coagulase-negative Staphylococci and S aureus were NS to oxacillin in 91.44% and 56.03%, respectively. Enterococcus spp was NS to vancomycin in 42.31% of the cases. Conclusions: DA-HAI rates and bacterial resistance are high and continuous efforts are needed to reduce them.
AB - Background: We report the results of INICC surveillance study from 2013 to 2018, in 664 intensive care units (ICUs) in 133 cities, of 45 countries, from Latin-America, Europe, Africa, Eastern-Mediterranean, Southeast-Asia, and Western-Pacific. Methods: Prospective data from patients hospitalized in ICUs were collected through INICC Surveillance Online System. CDC-NHSN definitions for device-associated healthcare-associated infection (DA-HAI) were applied. Results: We collected data from 428,847 patients, for an aggregate of 2,815,402 bed-days, 1,468,216 central line (CL)-days, 1,053,330 mechanical ventilator (MV)-days, 1,740,776 urinary catheter (UC)-days. We found 7,785 CL-associated bloodstream infections (CLAB), 12,085 ventilator-associated events (VAE), and 5,509 UC-associated urinary tract infections (CAUTI). Pooled DA-HAI rates were 5.91% and 9.01 DA-HAIs/1,000 bed-days. Pooled CLAB rate was 5.30/1,000 CL-days; VAE rate was 11.47/1,000 MV-days, and CAUTI rate was 3.16/1,000 UC-days. P aeruginosa was non-susceptible (NS) to imipenem in 52.72% of cases; to colistin in 10.38%; to ceftazidime in 50%; to ciprofloxacin in 40.28%; and to amikacin in 34.05%. Klebsiella spp was NS to imipenem in 49.16%; to ceftazidime in 78.01%; to ciprofloxacin in 66.26%; and to amikacin in 42.45%. coagulase-negative Staphylococci and S aureus were NS to oxacillin in 91.44% and 56.03%, respectively. Enterococcus spp was NS to vancomycin in 42.31% of the cases. Conclusions: DA-HAI rates and bacterial resistance are high and continuous efforts are needed to reduce them.
KW - Bacterial resistance
KW - Device-associated infection
KW - Health care-associated infection
KW - Hospital infection
KW - Limited resources countries
KW - Nosocomial infection
UR - https://www.scopus.com/pages/publications/85110454891
U2 - 10.1016/j.ajic.2021.04.077
DO - 10.1016/j.ajic.2021.04.077
M3 - Article
C2 - 33901588
AN - SCOPUS:85110454891
SN - 0196-6553
VL - 49
SP - 1267
EP - 1274
JO - American Journal of Infection Control
JF - American Journal of Infection Control
IS - 10
ER -